Table 2 Biological features of patients according to CD56 expression
From: Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia
Biological features | CD56(+) No(%) | CD56(−) No(%) | p |
|---|---|---|---|
AML1-ETO mutation(n = 145) | |||
Yes | 21(33.9%) | 24(28.9%) | 0.523 |
No | 41(66.1%) | 59(71.1%) | |
FLT3-ITD mutation(n = 145) | |||
Yes | 4(6.5%) | 9(10.8%) | 0.360 |
No | 58(93.5%) | 74(89.2%) | |
Complex karyotype(n = 145) | |||
Yes | 9 (14.5%) | 9 (10.8%) | 0.507 |
No | 53 (85.5%) | 74 (89.2%) | |
CD3(n = 119) | |||
Positive | 21(39.6%) | 27(40.9%) | 0.887 |
Negative | 32(60.4%) | 39(59.1%) | |
CD117(n = 123) | |||
Positive | 49(89.1%) | 64(94.1%) | 0.495 |
Negative | 6(10.9%) | 4(5.9%) | |
CD123(n = 97) | |||
Positive | 38(95.0%) | 50(87.7%) | 0.389 |
Negative | 2(5.0%) | 7(12.3%) | |
CD34(n = 121) | |||
Positive | 41(77.4%) | 58(85.3%) | 0.261 |
Negative | 12(22.6%) | 10(14.7%) | |